No Data
No Data
Jiangsu Hengrui Medicine Co., Ltd. Beat Revenue Forecasts By 12%: Here's What Analysts Are Forecasting Next
Research Reports Digging | Fangzheng Securities: jiangsu hengrui pharmaceuticals' performance in the first half of the year exceeds expectations, maintaining a "strong recommendation" rating
According to the research report of Founder Securities, Jiangsu Hengrui Pharmaceuticals (600276.SH) exceeded expectations in the H1 performance of 2024, with the clinical value of innovative achievements highlighted and the dual-drive performance growth of going international. Maintaining a "strong recommendation" rating. In the first half of the year, the company's revenue from innovative drugs reached 6.612 billion yuan (including tax, excluding foreign license income), achieving a year-on-year growth of 33% despite facing factors such as intensified competition, price reductions, and difficult access. The effectiveness of innovative drugs going international has become the second engine of performance growth. During the reporting period, the company has received 0.16 billion euros from Merck Healthcare for foreign licenses.
Jiangsu Hengrui Medicine Fiscal 2024 Profit Up 49%, Operating Income Rises 22%; Shares Up 3%
Jiangsu Hengrui Pharmaceuticals Semi-Annual Report for 2024
Jiangsu Hengrui Pharmaceuticals 2024 Interim Report Summary
Jiangsu Hengrui Medicine 1H Rev CNY13.60B Vs. CNY11.17B >600276.SH
No Data